Mylan Loses Duragesic Case; Generic Launch Timing Dispute Moves To FDA

The launch timing for the first generic version of Johnson & Johnson/Alza's Duragesic fentanyl patch will depend on FDA's decision about a six-month pediatric exclusivity extension for the product

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet